Compare VENUS REMEDIES with - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs ALKEM LABORATORIES - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES ALKEM LABORATORIES VENUS REMEDIES/
ALKEM LABORATORIES
 
P/E (TTM) x -1.0 - - View Chart
P/BV x 0.1 6.6 1.1% View Chart
Dividend Yield % 0.0 0.7 -  

Financials

 VENUS REMEDIES   ALKEM LABORATORIES
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-18
ALKEM LABORATORIES
Mar-16
VENUS REMEDIES/
ALKEM LABORATORIES
5-Yr Chart
Click to enlarge
High Rs1261,589 7.9%   
Low Rs611,232 5.0%   
Sales per share (Unadj.) Rs301.8417.5 72.3%  
Earnings per share (Unadj.) Rs-24.956.3 -44.2%  
Cash flow per share (Unadj.) Rs2.564.7 3.9%  
Dividends per share (Unadj.) Rs012.70 0.0%  
Dividend yield (eoy) %00.9 0.0%  
Book value per share (Unadj.) Rs293.3292.9 100.1%  
Shares outstanding (eoy) m12.34119.57 10.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.33.4 9.2%   
Avg P/E ratio x-3.825.1 -15.0%  
P/CF ratio (eoy) x36.721.8 168.6%  
Price / Book Value ratio x0.34.8 6.6%  
Dividend payout %022.6 0.0%   
Avg Mkt Cap Rs m1,154168,653 0.7%   
No. of employees `0000.9NA-   
Total wages/salary Rs m3939,171 4.3%   
Avg. sales/employee Rs Th4,026.1NM-  
Avg. wages/employee Rs Th425.0NM-  
Avg. net profit/employee Rs Th-331.8NM-  
INCOME DATA
Net Sales Rs m3,72449,915 7.5%  
Other income Rs m231,645 1.4%   
Total revenues Rs m3,74751,561 7.3%   
Gross profit Rs m3958,482 4.7%  
Depreciation Rs m3381,006 33.6%   
Interest Rs m354671 52.8%   
Profit before tax Rs m-2758,451 -3.3%   
Minority Interest Rs m0-114 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m321,606 2.0%   
Profit after tax Rs m-3076,731 -4.6%  
Gross profit margin %10.617.0 62.4%  
Effective tax rate %-11.519.0 -60.4%   
Net profit margin %-8.213.5 -61.1%  
BALANCE SHEET DATA
Current assets Rs m2,63827,062 9.7%   
Current liabilities Rs m2,30515,324 15.0%   
Net working cap to sales %8.923.5 38.0%  
Current ratio x1.11.8 64.8%  
Inventory Days Days13567 203.6%  
Debtors Days Days4641 112.2%  
Net fixed assets Rs m4,87112,610 38.6%   
Share capital Rs m123239 51.6%   
"Free" reserves Rs m3,49634,490 10.1%   
Net worth Rs m3,61935,027 10.3%   
Long term debt Rs m1,3741,212 113.4%   
Total assets Rs m7,50954,387 13.8%  
Interest coverage x0.213.6 1.6%   
Debt to equity ratio x0.40 1,097.9%  
Sales to assets ratio x0.50.9 54.0%   
Return on assets %0.613.6 4.6%  
Return on equity %-8.519.2 -44.1%  
Return on capital %1.624.9 6.4%  
Exports to sales %012.9 0.0%   
Imports to sales %13.93.1 449.5%   
Exports (fob) Rs mNA6,461 0.0%   
Imports (cif) Rs m5171,540 33.5%   
Fx inflow Rs m06,563 0.0%   
Fx outflow Rs m5173,012 17.1%   
Net fx Rs m-5173,552 -14.5%   
CASH FLOW
From Operations Rs m5147,259 7.1%  
From Investments Rs m-1231,864 -6.6%  
From Financial Activity Rs m-387-9,273 4.2%  
Net Cashflow Rs m4-150 -2.8%  

Share Holding

Indian Promoters % 32.9 66.9 49.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.2 33.1 0.5%  
FIIs % 0.6 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 0.0 -  
Shareholders   20,121 68,381 29.4%  
Pledged promoter(s) holding % 36.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   DISHMAN PHARMA  ELDER PHARMA  SUVEN LIFESCIENCES  PANACEA BIOTECH  WOCKHARDT  

Compare VENUS REMEDIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Extend Gains; Tata Motors & ONGC Climb 5%(12:30 pm)

Share markets in India have extended early morning gains and are presently trading higher. Investors are cautious ahead of the release of Consumer Price Index-based inflation.

Related Views on News

VENUS REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 11.1% (Quarterly Result Update)

Jun 12, 2019 | Updated on Jun 12, 2019

For the quarter ended March 2019, VENUS REMEDIES has posted a net profit of Rs 104 m (down 11.1% YoY). Sales on the other hand came in at Rs 864 m (down 7.3% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

VENUS REMEDIES Announces Quarterly Results (3QFY19); Net Profit Down 2301.8% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, VENUS REMEDIES has posted a net profit of Rs 119 m (down 2301.8% YoY). Sales on the other hand came in at Rs 691 m (down 25.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

VENUS REMEDIES 2017-18 Annual Report Analysis (Annual Result Update)

Dec 21, 2018 | Updated on Dec 21, 2018

Here's an analysis of the annual report of VENUS REMEDIES for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of VENUS REMEDIES. Also includes updates on the valuation of VENUS REMEDIES.

VENUS REMEDIES Announces Quarterly Results (2QFY19); Net Profit Down 16.3% (Quarterly Result Update)

Nov 23, 2018 | Updated on Nov 23, 2018

For the quarter ended September 2018, VENUS REMEDIES has posted a net profit of Rs 8 m (down 16.3% YoY). Sales on the other hand came in at Rs 809 m (down 10.6% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

VENUS REMEDIES Announces Quarterly Results (1QFY19); Net Profit Down 756.1% (Quarterly Result Update)

Aug 20, 2018 | Updated on Aug 20, 2018

For the quarter ended June 2018, VENUS REMEDIES has posted a net profit of Rs 56 m (down 756.1% YoY). Sales on the other hand came in at Rs 655 m (down 16.2% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

More Views on News

Most Popular

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

What if Indiabulls Housing Finance and Yes Bank Do Not Rebound?(Profit Hunter)

Oct 1, 2019

How long should you wait for fallen blue chips like Yes Bank and Indiabulls Housing Finance to rebound?

Rebound Riches Could be Yours With These Stocks(Profit Hunter)

Oct 4, 2019

The secret to multibagger is not big businesses, but great managements... Here's how to find them to make the most of once in a decade rebound opportunity.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

Foreign Money is Chasing Indian Stocks Once Again(The 5 Minute Wrapup)

Oct 4, 2019

Around Rs 75 billion poured into the Indian stock market in the month of September.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Oct 14, 2019 01:13 PM

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES 8-QTR ANALYSIS

COMPARE VENUS REMEDIES WITH

MARKET STATS